pregnancy outcomes - MGH Center for Women's Mental Health

SSRIs and Adverse Pregnancy Outcomes: Why You Can’t Just Read the Abstract

Over the past few years, there have been a large number of studies which have relied on large administrative databases to generate information on the reproductive safety of various medications. One of the strengths of this type of approach is that it provides an opportunity to observe outcomes in a large number of subjects; however, there are certain, very important limitations. A recent study published in the American Journal of Obstetrics and Gynecology helps to understand some of the challenges in interpreting the data generated from these studies.

By MGH Center for Women's Mental Health|2015-08-12T11:48:25-04:00September 20th, 2012|Psychiatric Disorders During Pregnancy|3 Comments

Pregnancy Outcomes in Women with Eating Disorders

Most studies have shown that women experience an improvement or remission in eating disorders during pregnancy; however, studies assessing how eating disorders may affect pregnancy outcomes have yielded conflicting results. While some studies have demonstrated no negative effects, others have demonstrated higher miscarriage rates among women with bulimia nervosa. In addition, women with histories of eating disorders have been shown to be significantly more likely to experience preterm delivery and to give birth to babies small for gestational age.

By MGH Center for Women's Mental Health|2015-08-12T12:10:02-04:00September 11th, 2012|Psychiatric Disorders During Pregnancy|1 Comment

Use of Antipsychotic Medications in Pregnancy Increases Risk of Gestational Diabetes

Atypical antipsychotic medications are commonly used for the treatment of schizophrenia and bipolar disorder. Despite the increasing use of these medications in women of child-bearing age, there is still relatively little data regarding the reproductive safety of these medications.

By Ruta Nonacs, MD PhD|2024-04-14T16:18:01-04:00July 17th, 2012|Psychiatric Disorders During Pregnancy|0 Comments

Topiramate (Topamax) Associated with an Increased Risk of Oral Clefts

Topiramate (marketed as a Topamax), in addition to its use for the treatment of epilepsy, is now being prescribed to reproductive aged women for a broad spectrum of indications, including migraine headaches, weight control, and mood stabilization. Limited information is available on its reproductive safety; however, the preliminary data we do have raises some concerns regarding the use of topiramate in pregnancy.

By MGH Center for Women's Mental Health|2015-08-12T16:57:19-04:00February 8th, 2012|Psychiatric Disorders During Pregnancy|2 Comments

Antidepressant Treatment During Pregnancy: One Woman’s Experience (Part II)

Part 2: Pregnancy

By MGH Center for Women's Mental Health|2015-07-28T14:42:32-04:00September 14th, 2011|Psychiatric Disorders During Pregnancy|3 Comments

What is the Impact of Depression During Pregnancy?

In a recent study by Gerardin and colleagues, the authors note that more research has been done to demonstrate the consequences of postpartum depression than depression during pregnancy (also called antenatal or prenatal depression). Infants born to mothers with depression during pregnancy have been demonstrated to have lower scores on motor behavior and more crying and irritability. Few studies, however, have assessed the longer-term effects of antenatal depression.

By MGH Center for Women's Mental Health|2015-07-28T14:40:30-04:00July 12th, 2011|Psychiatric Disorders During Pregnancy|3 Comments

Serotonin Reuptake Inhibitors and Fertility (Part 2): What Can Basic Science Tell Us?

Serotonin (5-HT) is one of the neurotransmitters involved in mood regulation and has been implicated in the development of mood and anxiety disorders. Serotonin transporters (SERT) facilitate the transfer of serotonin into neurons; serotonin reuptake inhibitor (SSRI) antidepressants bind to these transporters and appear to exert their effect on mood by inhibiting the reuptake of serotonin and thus increasing the levels of this neurotransmitter at the synapse.

By MGH Center for Women's Mental Health|2015-07-28T14:39:53-04:00July 5th, 2011|Infertility and Mental Health|1 Comment

Clinical Case: Should SSRIs Be Tapered Prior To Delivery?

Ms. T is a 33 year old woman with a history of recurrent depression who is 32 weeks pregnant with her first pregnancy. She has remained on her citalopram (Celexa) throughout pregnancy and has been well. Her gynecologist has encouraged her to enquire about coming off the Celexa prior to delivery in order to avoid symptoms of neonatal distress. What should she do?

By MGH Center for Women's Mental Health|2015-07-28T14:36:21-04:00June 13th, 2011|Psychiatric Disorders During Pregnancy|1 Comment

Zolpidem (Ambien) in Pregnancy: Is it Safe?

It is estimated that up to 95% of women experience some type of sleep disturbance during pregnancy. While for many women the insomnia is relatively benign and may respond to simple interventions, other women experience more severe insomnia which has a significant impact on their quality of life and ability to function. While zolpidem (Ambien), a sedative-hypnotic agent used for the short-term treatment of insomnia, is commonly prescribed in pregnant women, the information regarding its reproductive safety has been sparse.

By MGH Center for Women's Mental Health|2015-08-13T11:45:40-04:00November 22nd, 2010|Psychiatric Disorders During Pregnancy|15 Comments

ACOG Focuses on Smoking Cessation in Pregnant and Postpartum Women

In the November issue of Obstetrics & Gynecology, The American College of Obstetricians and Gynecologists (ACOG) has issued recommendations to providers regarding efforts to support smoking cessation in pregnant and postpartum women.

By MGH Center for Women's Mental Health|2017-05-05T11:50:17-04:00November 10th, 2010|Postpartum Psychiatric Disorders, Psychiatric Disorders During Pregnancy|0 Comments